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D
iabetes mellitus is the most
common endocrine disorder,
and the World Health Organi-
zation has estimated the number of dia-
betic patients rising up to 366 million
in the year 2030.1,2 Elevated blood
glucose levels are a hallmark of diabe-
tes mellitus. Diabetic patients have
a high risk of developing susceptibility
to infections and delayed healing,
atherosclerosis associated with myocar-
dial infarction and coronary artery dis-
ease, or neuropathy strokes.3,4 Beside
these life-threatening complications, dia-
betes affects bone metabolism that leads
to changes in bone structure, mineral
density, and the extent of their contribu-
tion to the increase of fracture risk.5–7
Uncontrolled diabetes is also a risk
factor in implant dentistry.7–9 Implant loss
in patients with uncontrolled diabetes
mellitus is signiﬁcant, especially within
the early phase of osseointegration.9,10
Blood glucose levels seemingly affect
the early implant stability, which is a sur-
rogate parameter of osseointegration.11
One strategy is strict glycemic controls,
but many patients exceed the therapeutic
range.12 Consequently, therapies to
improve the early stages of osseointegra-
tion in diabetic patients are demanding.
Parathyroid hormone (PTH) has
attracted interest as a bone anabolic
agent and is approved for the therapy
of osteoporosis.13 In addition to the
beneﬁcial effect of PTH on bone
remodeling, preclinical studies have
demonstrated the positive effect of
PTH on fracture healing.14–20 Recently,
also clinical evidence that PTH supports
fracture healing became available.21,22 A
recent clinical study showed the positive
effect of PTH on bone regeneration
after periodontal surgery.23 Moreover,
PTH has been shown to stimulate the
process of osseointegration in preclini-
cal models,20,24 and clinical pilot studies
were also performed.25 The spectrum of
indication for the administration of PTH
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Objectives: Uncontrolled diabe-
tes mellitus is associated with
impaired osseointegration. Diabetic
individuals might beneﬁt from bone
anabolic therapies. Intermittent
administration of 1-34 parathyroid
hormone (PTH) stimulates bone for-
mation in rodent models. However,
this anabolic effect fails in diabetic
rats. Whether the anabolic effect of
PTH can be achieved in insulin-
controlled diabetic rats has not been
investigated yet.
Materials and Methods: After
diabetes induction with streptozoto-
cin in 40 female Wistar rats, the
animals were randomly divided into
4 groups: diabetes, diabetes plus
PTH, insulin-treated diabetes, and
insulin-treated diabetes plus PTH.
After 1 week, miniscrews were in-
serted in the tibiae. Osmotic pumps
with insulin or saline solution were
implanted. Animals received 60
mg/kg PTH or saline solution. His-
tomorphometric analysis was per-
formed.
Results: In diabetic rats, no
changes of medullary periimplant
bone area or bone-to-implant con-
tacts (BICs) were achieved with or
without treatment with PTH. How-
ever, also animals treated with insu-
lin failed to response signiﬁcantly to
PTH regarding bone area (7.4 6
4.1% and 8.1 6 4.1%) and BICs
(33.7 6 16.9% and 49.9 6 11.9%).
Conclusion: These results dem-
onstrate that the metabolic charac-
teristics of the diabetic rats produced
a condition unable to respond to
PTH treatment, even when hypergly-
cemia was controlled with insulin.
(Implant Dent 2015;24:392–396)
Key Words: bone, teriparatide,
rodent model, hyperglycemia
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is rising, but it remains unknown how
metabolic changes inﬂuence the effect
of PTH.
A recent study has shown that PTH
fails to enhance osseointegration in an
experimental type 1 diabetes model.26
Thus, the general held view that inter-
mittent administration of PTH improves
the process of bone regenerationnot nec-
essarily accounts true for compromised
situations in diabetic patients. This has
prompted us to suggest that PTH can
exert its anabolic function when type 1
diabetes is controlled by insulin. We
therefore tested the effect of PTH os-
seointegration in type 1 diabetic rats
treated with insulin.
MATERIALS AND METHODS
Study Design, Ethics, and Induction
of Diabetes
Forty 6-month-old female Wistar
rats from the Division for Biomedical
Research (Himberg, Austria) were used
for this study. The animals were treated
according to the guidelines for animal
care with free access to water and
a standard diet. The rats were divided
into 4 groups: diabetes, diabetes and
PTH, insulin-treated diabetes, and insu-
lin-treated diabetes with PTH. The type
1 diabetes was induced with a single
intraperitoneal dose of 45 mg/kg strep-
tozotocin (STZ; Sigma, St. Louis, MO)
in citrate buffer. Weights and blood
glucose levels were monitored at the
day of implantation and at the day of
being killed. Rats were considered as
diabetic, if blood glucose levels ex-
ceeded 200 mg/dL. The Medical Uni-
versity ofVienna Ethical ReviewBoard
for Animal Research approved the
study protocol (GZ 66.009/0275-II/
10b/2008).
Surgical Procedures and
Postoperative Treatment
One week after diabetes induction,
the implant surgery was performed.
Before the surgery, all animals received
ketamine (100 mg/kg; Pharmacia &
Upjohn, Erlangen, Germany) and xyla-
zine hydrochloride (5 mg/kg; Bayer,
Leverkusen, Germany) by intramuscu-
lar injection.An incisionwasmade over
the proximal metaphysis of the left
tibia, and muscles and periosteum were
displaced. Ten millimeters below the
knee joint, a hole was drilled and a tita-
nium miniscrew (diameter 1 mm,
length 3 mm; Medos Medizintechnik,
Vienna, Austria) was inserted. To
install the osmotic pumps (Osmotic
pump Model 2ML4; Alzet Technical
Fig. 1. Periimplant bone area (BV/TV): Medullary and cortical compartments. Type 1 diabetes
was induced with intraperitoneal streptozotocin (STZ). Insulin was applied through osmotic
pumps. The pump was ﬁlled with insulin (Humulin R [100 IU/mL] providing approximately 2
units per day; Eli Lilly and Company). Rats received 60 mg PTH per kilogram body weight 3
times per week for 4 weeks.
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Support, DURECT Corporation, Cu-
pertino, CA), a horizontal incision was
made at the dorsal neck, and by blunt
dissection, the subcutaneous tissues
between the shoulder blades were
expanded to create space for the
osmotic pump. The pumps were ﬁlled
with insulin (Humulin R [100 IU/mL]
providing approximately 2 units per
day; Eli Lilly and Company USA,
LLC, Indianapolis, IN) or physiologic
saline solution. Wounds were closed
with resorbable sutures (Vicryl5-0;Ethi-
conGmbH,Norderstedt,Germany).Bu-
torphanol (0.05 mg/kg; Fort Dodge
Laboratories,Girona, Spain)was admin-
istered for pain relief. A sterile solution
of 60mg recombinant rat 1-34PTH(#H-
5460;Bachem,Bubendorf, Switzerland)
per 1 mL vehicle (10 mM citric acid and
2% heat inactivated rat serum) was pre-
paredweekly and stored at 4°C until use.
Three times per week, rats received 60
mg PTH per kilogram body weight or
avehicleby subcutaneous injection, start-
ing at the day of implant placement. After
4weeks, the animalswere killed by intra-
peritoneal injection of thiopental (150
mg/kg; Nycomed, Konstanz, Germany).
Sample Processing
The tibiae were removed and ﬁxed
in phosphate-buffered formalin (Roti-
Histoﬁx 4%; Carl Roth, Karlsruhe,
Germany). The samples were dehy-
drated with ascending alcohol grades
and embedded in light-curing resin
(Technovit 7200 VLC + BPO; Kulzer
& Co., Wehrheim, Germany). Blocks
were further processed by using
EXAKT cutting and grinding equip-
ment (Exakt Apparatebau, Norder-
stedt, Germany) to thin ground
sections along the implant axis. The
sections were stained according to the
method of Levai-Laczko. Sections
were scanned with Olympus BX61VS
microscope (Olympus Deutschland,
Hamburg, Germany). Medullary and
cortical compartments in an area of
200 mm around the screw were deﬁned
as regions of interest (ROI). The im-
ages were analyzed based on rule
sets considering the color and shape
of the structures in the ROI with Deﬁn-
iens Developer XD2.0 (Deﬁniens, Mu-
nich, Germany) followed by manual
control using Photoshop (Adobe, San
Jose, CA).
Histomorphometric Analysis
Within the 200 mm of the ROI, 2
parameters were recorded: The percent-
age of present bone in the ROI was
Fig. 2. Bone-to-implant contact (BIC): Medullary and cortical compartments. Type 1 diabetes
was induced with intraperitoneal streptozotocin (STZ). Insulin was applied through osmotic
pumps. The pump was ﬁlled with insulin (Humulin R [100 IU/mL] providing approximately 2
units per day; Eli Lilly and Company). Rats received 60 mg PTH per kilogram body weight 3
times per week for 4 weeks.
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determined as “bone volume per tissue
volume” (BV/TV), and screw surface in
contact with bone was called “bone-to-
implant contact” (BIC) and calculated
as a percentage. Although this bone
area is a 2-dimensional measurement,
it is proportional to the 3-dimensional
volume of bone. The medullary and
cortical compartments were analyzed
separately according to BV/TV and
BIC (Figs. 1 and 2). The proximal 400
mm of the medullary compartment was
excluded of the analysis because of pos-
sible drilling dust.26 Screws with close
proximity to the cortical bone were also
excluded of the study because these sit-
uations can act as an osteoconductive
bone graft on the local bone, irrespec-
tive of the treatment.
Statistics
Mean values of BV/TV and BIC
were compared in the medullary and
cortical compartments of diabetic rats
or animals treated with PTH by two-
way analysis of variance on the data. In
case of a signiﬁcance, post hocmultiple
t-tests were conducted to test the PTH
effect, both in the control and the dia-
betes group. The Benjamini-Hochberg
procedure was applied to correct for
multiple testing, and signiﬁcance was
assigned at the 5% level.
RESULTS
Effects of STZ and Insulin Treatment
Blood glucose levels beyond 200
mg/dL are a determinant of diabetes.
The blood glucose levels of the animals
rose after STZ administration up to an
average value of 431 mg/dL within
aweek and up to 579mg/dL throughout
the experiment. Due to the insulin
treatment, the blood glucose levels in
the medicated rats fell again to normal
values (mean: 175 mg/dL).
Evaluation of PTH Effect on
Osseointegration in the
Medullary Compartment
As previously reported, PTH in-
creases the BV/TV in a normoglycemic
group but not in type 1 diabetic rats.26
Also in this study, no increase of medul-
laryBV/TVwasachieved indiabetic rats
treatedwith PTH (15.86 14.8% and 9.0
6 8.6%). The same applies true for BIC
(43.6 6 13.6% and 40.2 6 18.7%).
New, however, is that type 1 diabetic rats
treated with insulin showed no increase
in BV/TV or BIC under PTH treatment
(8.1 6 4.1% and 7.4 6 4.1%; 49.9 6
11.9% and 33.76 16.9%, respectively).
Thus, insulin alone cannot reverse sus-
ceptibility of type 1 diabetic rats to
respond to PTH in a tibia implantation
model.
Evaluation of PTH Effect on
Osseointegration in the
Cortical Compartment
In support of previous observation
in normoglycemic and type 1 diabetic
rats,24,26,27 the cortical BC/TV was sim-
ilar in all treatment groups: diabetes,
diabetes plus PTH, insulin-treated dia-
betes, and insulin-treated diabetes plus
PTH(84.86 7.9%,86.16 4.4%,91.06
5.2%, and 85.4 6 3.1%, respectively).
The same accounts true for BICs where
PTH had no considerable impact on os-
seointegration in diabetic rats that
remain untreated or when glucose lev-
els were controlled with insulin (79.46
13.0%, 75.1 6 12.7%, 81.2 6 14.4%,
and 75.66 9.2%, respectively).
DISCUSSION
Based on our previous observa-
tions that type 1 diabetes lowers the
impact of PTH on medullary osseointe-
gration,26 we hypothesized that correct-
ing blood glucose make animals
susceptible for the anabolic effects of
PTH. The main ﬁnding of this study
was, however, that PTH failed to
improve osseointegration in diabetic
rats treated with insulin. These observa-
tions are important as they suggest that
correcting blood glucose alone is not
enough make the animals susceptible
for PTH in the present model.
If we relate our ﬁndings to those of
others, our data are in linewith previous
data showing around 15% medullary
BV/TV in control and STZ-treated rats.
Surprisingly, however, previous data
showed approximately 15% medullary
BIC, whereas here we have measured
around 40% BIC, indicating that
the models cannot directly be com-
pared. The underlying reasons remain
unknown. This study can, however,
conﬁrm previous observations that
PTH fails to support osseointegration
in type 1 diabetic rats,26 possibly
involving deterioration of the insulin-
like growth factor 1 (IGF-1) levels.28–30
In this study, insulin pumps lowered the
blood glucose to almost normoglyce-
mic conditions. However, since we
have not measured the impact of insulin
on the IGF-1 serum levels, we have to
consider this as a study limitation. It is
thus possible that IGF-1 levels are still
below the threshold required to exert
the anabolic effects of PTH in vivo.
The clinical relevance of the pres-
ent ﬁnding has to be interpreted with
care as the model only partially reﬂects
the situating in patients. Obviously,
rodent models heal faster than humans,
the tibia is not the alveolar bone,
and the uncontrolled type 1 diabetes
with the massive hyperglycemia is
a rare situation. Clearly, this is a proof
of principles study with one observa-
tion period. Thus, it cannot be ruled out
that at other time points, PTH might
have supported osseointegration in the
insulin-treated rat models, for exam-
ple, when considered that after 4
weeks, almost half of the implant
surface is covered by bone. Overall,
the data provide further support for the
idea that severe diabetes, even when
partially controlled by insulin, ham-
pers the anabolic effect of PTH on
osseointegration in rat.
A study limitation is that we have
not included a normoglycemic control to
prove that PTH exerts its anabolic func-
tion in this study. However, for ethical
reasons, and because there is plenty of
evidence including from our previous
research that PTH stimulates osseointe-
gration of miniscrews in the medullary
part of the tibia,27 we have avoided to
include these groups. Under the premise
of these limitations, our data suggest that
insulin treatment cannot reverse the ana-
bolic effect of PTH on osseointegration
in type 1 diabetic rat models.
CONCLUSION
The results of this study demon-
strate that the metabolic characteristics
of the diabetic rats produced a condition
unable to respond to PTH treatment,
even when hyperglycemia was con-
trolled with insulin.
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